Antibody Therapeutics for Life

Notices


No Title Written by Written date Inquire
17   Dr. Lawrence Cher at Olivia Newton-Johns Cancer Wellness & Research Center/Austin Hospital is invited to present the interim data of Tanibirumab phase IIa recurrent GBM trial at 2017 SNO (Society for Neuro Oncology) meeting in San Francisco on November 16   관리자   2019-01-14   167  
16   PharmAbcine`s ``BI(Business Incubation) Research Grant`` proposal is granted by KIAT.   관리자   2019-01-14   168  
15   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present for ``Investor Relation`` at MIRAE ASSET DAEWOO SECURITIES Corporate Day on July 12th, 2017.   관리자   2019-01-14   162  
14   Interview of Dr. Jin-San Yoo, CEO of PharmAbcine with Bio-Pod   관리자   2019-01-14   164  
13   Dr. Jin-San Yoo, CEO of PharmAbcine is presenting at the forum for future pharm in Seoul on June 23, 2017.   관리자   2019-01-14   164  
12   Dr. Jin-San Yoo, CEO of PharmAbcine is presenting PharmAbcine`s R&D progress and the interim data of the ongoing phase IIa recurrent GBM trial at 2017 Bio International Convention in San Diego on June 19-22, 2017.   관리자   2019-01-14   161  
11   Dr. Lawrence Cher, principle investigator of Tanibirumab phase IIa recurrent GBM trial in Australia expose the interim data of the ongoing trial at ASCO 2017 Annual Meeting in Chicago on June 2-6, 2017.   관리자   2019-01-14   161  
10   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present PharmAbcine`s R&D progress at BIO LOGISTICS WORLD KOREA in Seoul on May 23-24, 2017.   관리자   2019-01-14   157  
9   Dr. Jin-San Yoo, CEO of PharmAbcine is serving as an expert of MAB working group of EDQM observer representing Republic of Korea.   관리자   2019-01-14   160  
8   Dr. Jin-San Yoo, CEO of PharmAbcine is serving as an officer for Bio at the Med term Strategy and planning for pharma industry.   관리자   2019-01-14   352